CDMO Strength ABL offers GMP manufacturing, cell banks, and viral vector production from bench to Phase I/II, presenting a near-term sales opportunity to biopharma firms advancing gene therapies, vaccines, and oncolytic programs seeking experienced CDMO support.

Preclinical to Clinic With a historical focus on supporting candidate vaccines and therapeutics through preclinical and clinical development, ABL is well-positioned to engage sponsors early in development for integrated testing, analytics, and process development services.

Analytical & QA Capabilities ABL's strong analytical testing, release testing, and process development capabilities enable cross-sell to clients needing end-to-end quality assurance and regulatory-ready manufacturing support for complex biologics and gene therapies.

Longstanding Government Experience A 60+ year history as a biomedical research contractor to federal government signals reliability and compliance maturity, making ABL attractive for government-funded or grant-backed collaborations and to clients prioritizing risk management.

Strategic Partnerships ABL positions as a seamless extension of clients’ teams across US facilities, offering integrated services from bulk drug substance to fill/finish, which can be pitched to accelerate timelines and reduce vendor fragmentation for mid-to-late-stage programs.